These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

239 related items for PubMed ID: 16545729

  • 1. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
    Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, Kliem C, Pulsipher M, Maziarz RT, McSweeney PA, Wade J, Langston AA, Chauncey TR, Bruno B, Blume KG, Storb R.
    Biol Blood Marrow Transplant; 2006 Apr; 12(4):454-65. PubMed ID: 16545729
    [Abstract] [Full Text] [Related]

  • 2. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
    Koh LP, Chen CS, Tai BC, Hwang WY, Tan LK, Ng HY, Linn YC, Koh MB, Goh YT, Tan B, Lim S, Lee YM, Tan KW, Liu TC, Ng HJ, Loh YS, Mow BM, Tan DC, Tan PH.
    Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
    [Abstract] [Full Text] [Related]

  • 3. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
    Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF.
    Blood; 2003 Feb 15; 101(4):1620-9. PubMed ID: 12393457
    [Abstract] [Full Text] [Related]

  • 4. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
    Pérez-Simón JA, Martino R, Caballero D, Valcarcel D, Rebollo N, de la Cámara R, de Oteiza JP, Heras I, Calvo MV, Sierra J, San Miguel JF, Grupo Español de Trasplante Hematopoyético (GETH).
    Biol Blood Marrow Transplant; 2008 Jun 15; 14(6):664-71. PubMed ID: 18489992
    [Abstract] [Full Text] [Related]

  • 5. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
    Baron F, Sandmaier BM, Storer BE, Maris MB, Langston AA, Lange T, Petersdorf E, Bethge W, Maziarz RT, McSweeney PA, Pulsipher MA, Wade JC, Chauncey TR, Shizuru JA, Sorror ML, Woolfrey AE, Maloney DG, Storb R.
    Biol Blood Marrow Transplant; 2007 Sep 15; 13(9):1041-8. PubMed ID: 17697966
    [Abstract] [Full Text] [Related]

  • 6. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.
    Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB, Shpall EJ, Rabinovitch R, Zeng C, Barón A, McSweeney PA.
    Biol Blood Marrow Transplant; 2006 Feb 15; 12(2):217-25. PubMed ID: 16443519
    [Abstract] [Full Text] [Related]

  • 7. Cyclosporine and mycophenolate mofetil prophylaxis with fludarabine and melphalan conditioning for unrelated donor transplantation: a prospective study of 22 patients with hematologic malignancies.
    Rodriguez R, Parker P, Nademanee A, Smith D, O'Donnell MR, Stein A, Snyder DS, Fung HC, Krishnan AY, Popplewell L, Cohen S, Somlo G, Angelopoulou M, Al-Kadhimi Z, Falk PM, Spielberger R, Kogut N, Sahebi F, Senitzer D, Slovak M, Schriber J, Forman SJ.
    Bone Marrow Transplant; 2004 Jun 15; 33(11):1123-9. PubMed ID: 15064696
    [Abstract] [Full Text] [Related]

  • 8. Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial.
    Nakamae H, Storer BE, Storb R, Storek J, Chauncey TR, Pulsipher MA, Petersen FB, Wade JC, Maris MB, Bruno B, Panse J, Petersdorf E, Woolfrey A, Maloney DG, Sandmaier BM.
    Biol Blood Marrow Transplant; 2010 Mar 15; 16(3):384-94. PubMed ID: 19900571
    [Abstract] [Full Text] [Related]

  • 9. Effects of extending the duration of postgrafting immunosuppression and substituting granulocyte-colony-stimulating factor-mobilized peripheral blood mononuclear cells for marrow in allogeneic engraftment in a nonmyeloablative canine transplantation model.
    Zaucha JM, Yu C, Zellmer E, Takatu A, Junghanss C, Little MT, Storb R.
    Biol Blood Marrow Transplant; 2001 Mar 15; 7(9):513-6. PubMed ID: 11669218
    [Abstract] [Full Text] [Related]

  • 10. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T, Harpel J, Schuster MW, Roboz GJ, Leonard JP, Coleman M, Feldman EJ, Silver RT.
    Biol Blood Marrow Transplant; 2006 Aug 15; 12(8):868-75. PubMed ID: 16864057
    [Abstract] [Full Text] [Related]

  • 11. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
    Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D, Petersdorf E, McSweeney P, Pulsipher M, Woolfrey A, Chauncey T, Agura E, Heimfeld S, Slattery J, Hegenbart U, Anasetti C, Blume K, Storb R.
    Blood; 2003 Sep 15; 102(6):2021-30. PubMed ID: 12791654
    [Abstract] [Full Text] [Related]

  • 12. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
    Georges GE, Maris M, Sandmaier BM, Malone DG, Feinstein L, Niederweiser D, Shizuru JA, McSweeney PA, Chauncey TR, Agura E, Little MT, Sahebi F, Hegenbart U, Pulsipher MA, Bruno B, Forman S, Woolfrey AE, Radich JP, Blume KG, Storb R.
    Int J Hematol; 2002 Aug 15; 76 Suppl 1():184-9. PubMed ID: 12430851
    [Abstract] [Full Text] [Related]

  • 13. Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood hematopoietic cell transplantation for bone marrow failure syndromes.
    Pantin J, Tian X, Shah AA, Kurlander R, Ramos C, Cook L, Khuu H, Stroncek D, Leitman S, Barrett J, Donohue T, Young NS, Geller N, Childs RW.
    Am J Hematol; 2013 Oct 15; 88(10):874-82. PubMed ID: 23813900
    [Abstract] [Full Text] [Related]

  • 14. G-CSF-mobilized peripheral blood mononuclear cells added to marrow facilitates engraftment in nonmyeloablated canine recipients: CD3 cells are required.
    Zaucha JM, Zellmer E, Georges G, Little MT, Storb R, Storer B, Torok-Storb B.
    Biol Blood Marrow Transplant; 2001 Oct 15; 7(11):613-9. PubMed ID: 11760149
    [Abstract] [Full Text] [Related]

  • 15. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation.
    Baron F, Maris MB, Storer BE, Sandmaier BM, Panse JP, Chauncey TR, Sorror M, Little MT, Maloney DG, Storb R, Heimfeld S.
    Leukemia; 2005 May 15; 19(5):822-8. PubMed ID: 15772701
    [Abstract] [Full Text] [Related]

  • 16. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.
    Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R.
    Biol Blood Marrow Transplant; 2005 Jul 15; 11(7):495-505. PubMed ID: 15983549
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
    Feinstein LC, Sandmaier BM, Maloney DG, Maris MB, Gooley TA, Chauncey TR, Hegenbart U, McSweeney PA, Stuart MJ, Forman SJ, Agura EA, Pulsipher MA, Blume KG, Niederwieser DW, Storb RF.
    Biol Blood Marrow Transplant; 2003 Apr 15; 9(4):266-72. PubMed ID: 12720219
    [Abstract] [Full Text] [Related]

  • 19. Stable engraftment after a conditioning regimen with fludarabine and melphalan for bone marrow transplantation from an unrelated donor.
    Inamoto Y, Oba T, Miyamura K, Terakura S, Tsujimura A, Kuwatsuka Y, Tokunaga M, Kasai M, Murata M, Naoe T, Kodera Y.
    Int J Hematol; 2006 May 15; 83(4):356-62. PubMed ID: 16757439
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.